Download PDF

1. Company Snapshot

1.a. Company Description

Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the stability of shipped biologic commodities is maintained throughout the shipping cycle.It also provides information dashboards and validation documentation for shipments through data collected by the SmartPak Condition Monitoring System; and vacuum insulated aluminum dewars and cryogenic freezers systems.


In addition, the company offers biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; transportation of frozen biological specimens to and from customer locations; and management of incoming and outgoing biological specimens, as well as provides logistics support and management; and short-term logistics and engineering consulting services.It serves biopharma/pharma, animal health, and human reproductive medicine markets.The company was founded in 1999 and is headquartered in Brentwood, Tennessee.

Show Full description

1.b. Last Insights on CYRX

The recent earnings release of Cryoport, Inc. revealed a loss of $0.42 per share in Q4 2024, surpassing the Zacks Consensus Estimate of a loss of $0.33. While revenue of $228.4 million aligned with company guidance, the commercial cell & gene therapy revenue rose 20% year-over-year. However, the company's high medical care ratios and increasing costs may have contributed to the loss, despite a record number of 701 global clinical trials supported.

1.c. Company Highlights

2. Cryoport's 2025 Earnings: A Year of Record Growth

Cryoport reported a strong financial performance for 2025, with revenue from continuing operations reaching $176.2 million, exceeding the high end of prior guidance. The company's Life Sciences Services segment drove this growth, with an 18% year-over-year increase, including a 22% growth in BioStorage/BioServices revenue. Commercial cell and gene therapy revenue also saw a significant surge, growing 29% year-over-year to a record $33.4 million. The company's gross margin stood at 47%, and adjusted EBITDA improved by $12 million year-over-year. Cryoport's EPS came in at -$0.21, slightly missing estimates of -$0.19.

Publication Date: Mar -08

📋 Highlights

Segment Performance

The Life Sciences Services segment was the primary driver of Cryoport's growth in 2025, with revenue increasing 18% year-over-year. The BioStorage/BioServices business within this segment saw a 22% revenue growth, contributing significantly to the company's overall performance. The Life Sciences Products segment, which includes MVE Biological Solutions, grew 7% year-over-year, with the launch of innovative products such as integrated condition monitoring solutions and the Fusion 800 Series cryogenic freezer.

Outlook for 2026

Cryoport expects continued growth in 2026, driven by its commercial cell and gene therapy business. The company anticipates revenue of $190 million to $194 million for the full year, representing a growth rate of around 9%, which is slightly above analyst estimates of 9.5%. The company is also expecting positive adjusted EBITDA in the second half of 2026. With 86 clinical trials in Phase III and 361 in Phase II, Cryoport is well-positioned for future growth.

Valuation

Cryoport's current valuation metrics indicate a mixed picture. The company's Price-to-Sales Ratio stands at 2.3, while the EV/EBITDA ratio is negative at -33.06, reflecting the company's current loss-making position. The ROE is 16.44%, indicating a decent return on equity. With the current valuation, the market seems to be pricing in a moderate growth trajectory for the company.

3. NewsRoom

Card image cap

Cryoport, Inc. (CYRX) Q4 2025 Earnings Call Transcript

Mar -04

Source: seekingalpha.com

Card image cap

CryoPort, Inc. (CYRX) Reports Q4 Loss, Tops Revenue Estimates

Mar -03

Source: zacks.com

Card image cap

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

Mar -03

Source: prnewswire.com

Card image cap

Cryoport to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Feb -17

Source: prnewswire.com

Card image cap

Cryoport's MVE Biological Solutions Introduces New Fusion® 800 Series

Feb -11

Source: prnewswire.com

Card image cap

EXCLUSIVE: New Fusion 800 Launch Signals Cryoport's Ambition To Modernize Cryogenic Storage

Feb -11

Source: feeds.benzinga.com

Card image cap

CryoPort (NASDAQ:CYRX) vs. Royal Mail (OTCMKTS:ROYMY) Head-To-Head Contrast

Jan -13

Source: defenseworld.net

Card image cap

CryoPort, Inc. (NASDAQ:CYRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Jan -07

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.96%)

6. Segments

Biopharma/Pharma

Expected Growth: 8%

Cryoport's 8% growth in Biopharma/Pharma is driven by increasing demand for cell and gene therapies, expansion of clinical trials, and rising adoption of cryogenic logistics. Additionally, growing partnerships with pharmaceutical companies, increasing regulatory approvals, and investments in digital platforms are contributing to the segment's growth.

Animal Health

Expected Growth: 7%

Cryoport's Animal Health segment growth is driven by increasing demand for biologics and regenerative medicine, expansion of existing customer relationships, and strategic partnerships. The growing need for temperature-controlled logistics in animal health research and commercialization also contributes to this 7% growth.

Human Reproductive Medicine

Expected Growth: 10%

Cryoport's Human Reproductive Medicine segment growth is driven by increasing demand for fertility treatments, advancements in cryopreservation technology, and strategic partnerships with leading fertility clinics. Additionally, growing awareness of egg and sperm freezing, coupled with an aging population, fuels the need for reliable cryogenic logistics solutions, propelling Cryoport's 10% growth.

7. Detailed Products

Cryoport Express

A portable, dry vapor shipper that uses liquid nitrogen to maintain extremely low temperatures during transportation

Cryoport Express 3

A high-performance, dry vapor shipper designed for the transportation of high-value, temperature-sensitive materials

Cryopack 3

A high-performance, dry vapor shipping system designed for the transportation of high-value, temperature-sensitive materials

Cryologics

A cloud-based logistics platform that provides real-time monitoring and tracking of temperature-sensitive shipments

Cryoportal

A cloud-based platform that provides real-time monitoring and tracking of temperature-sensitive shipments, as well as data analytics and reporting

Cryogenic Storage

A cryogenic storage service that provides secure, temperature-controlled storage for biological samples and other temperature-sensitive materials

8. Cryoport, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Cryoport's cryogenic logistics services are highly specialized and there are limited substitutes available, reducing the threat of substitutes.

Bargaining Power Of Customers

Cryoport's customers, such as pharmaceutical and biotechnology companies, have some bargaining power due to their large orders, but Cryoport's specialized services and strong relationships mitigate this power.

Bargaining Power Of Suppliers

Cryoport has a diversified supplier base and is not heavily dependent on a single supplier, reducing the bargaining power of suppliers.

Threat Of New Entrants

The cryogenic logistics industry has low barriers to entry, and new entrants could potentially disrupt Cryoport's market share, especially with the increasing demand for cryogenic logistics services.

Intensity Of Rivalry

The cryogenic logistics industry is moderately competitive, with a few established players, but Cryoport's strong brand reputation and specialized services help to differentiate it from competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 44.09%
Debt Cost 3.95%
Equity Weight 55.91%
Equity Cost 11.93%
WACC 8.41%
Leverage 78.87%

11. Quality Control: Cryoport, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Pitney Bowes

A-Score: 5.4/10

Value: 6.7

Growth: 1.1

Quality: 5.2

Yield: 7.0

Momentum: 8.0

Volatility: 4.3

1-Year Total Return ->

View Full Report
Stock-Card
Napco Security Technologies

A-Score: 5.0/10

Value: 1.2

Growth: 8.8

Quality: 8.8

Yield: 1.0

Momentum: 6.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Cryoport

A-Score: 4.7/10

Value: 8.3

Growth: 4.2

Quality: 7.0

Yield: 0.0

Momentum: 7.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Radiant Logistics

A-Score: 3.9/10

Value: 5.8

Growth: 4.0

Quality: 4.4

Yield: 0.0

Momentum: 2.5

Volatility: 6.7

1-Year Total Return ->

View Full Report
Stock-Card
Air T

A-Score: 3.6/10

Value: 7.0

Growth: 5.4

Quality: 2.1

Yield: 0.0

Momentum: 5.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Forward Air

A-Score: 2.3/10

Value: 5.8

Growth: 2.4

Quality: 2.0

Yield: 0.0

Momentum: 1.5

Volatility: 2.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

8.01$

Current Price

8.01$

Potential

-0.00%

Expected Cash-Flows